A recent report also revealed an intriguing role for TIM3 as a growth suppressive receptor in melanoma cells, implying that systemic blockade of TIM3 along with TIL-ACT may offer limited benefits as compared to TIM3 KO in TILs for treating melanoma patients.30 This evidence concerns the gene HAVCR2 and melanoma.